COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,490 Articles (22,862 medRxiv, 8,628 bioRxiv)

Most recent first Previous |  Page 1240: Articles 12391-12400  | Next

COVID-19 Vaccination Strategies Considering Hesitancy Using Particle-Based Epidemic Simulation
Karabay, A., Kuzdeuov, A., Varol, H. A.
10.1101/2021.09.26.21264153 — Posted: 2021-09-28
Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac
Patamatamkul, S., Buranrat, B., Thammawat, S.
10.1101/2021.09.25.21264099 — Posted: 2021-09-28
A standardized instrument quantifying risk factors associated with bi-directional transmission of SARS-CoV-2 and other zoonotic pathogens: The COVID-19 Human-Animal Interactions Survey (CHAIS)
Gass, J. D., Waite, K. B., Hill, N., Dalton, K., Sawatzki, K., Runstadler, J. A., Davis, M. F., CHAIS Expert Review Group
10.1101/2021.09.21.21263227 — Posted: 2021-09-28
Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021
Ren, Z., Furukawa, K., Nishimura, M., Kurahashi, Y., Sutandhio, S., Tjan, L. H., Aoki, K., Hasegawa, N., Arii, J., Uto, K., Matsui, K., Sato, I., Saegusa, J., Godai, N., Takeshita, K., Yamamoto, M., Nagashima, T., Mori, Y.
10.1101/2021.09.26.21264129 — Posted: 2021-09-28
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., Slim, M. A., Schinkel, M., Wynberg, E., van Willigen, H. D. G., Grobben, M., Tejjani, K., Snitselaar, J. L., Caniels, T. G., Vlaar, A. P. J., Prins, M., de Jong, M. D., de Bree, G., Sikkens, J. J., Bomers, M. K., Sanders, R. W.
10.1101/2021.09.27.21264163 — Posted: 2021-09-28 Discussion: Onsite
Bayesian Inference of State-Level COVID-19 Basic Reproduction Numbers across the United States
Mallela, A., Neumann, J., Miller, E. F., Chen, Y., Posner, R. G., Lin, Y. T., Hlavacek, W. S.
10.1101/2021.09.27.21264188 — Posted: 2021-09-28 Discussion: Onsite
The Kinetics of COVID-19 Vaccine Response in a Community Vaccinated Population
Tu, M., Chiang, S. H., Bender, R., Wong, D., Strom, C.
10.1101/2021.09.18.21263605 — Posted: 2021-09-28
Global Burden of Covid-19 Restrictions: National, Regional and Global Estimates
Fink, G., Tediosi, F., Felder, S.
10.1101/2021.09.21.21263825 — Posted: 2021-09-28
Effectiveness of the mRNA BNT162b2 vaccine against SARS-CoV-2 severe infections in the Israeli over 60 population: a temporal analysis done by using the national surveillance data.
De Leo, S.
10.1101/2021.09.27.21264130 — Posted: 2021-09-28 Discussion: Onsite
Sub-Saharan African Countries' COVID-19 Research: An analysis of the External and Internal Contributions, Collaboration Patterns and Funding Sources
Asubiaro, T. V., Shaik, H.
10.1101/2021.09.27.21264044 — Posted: 2021-09-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).